ClinicalTrials.gg
CompletedNCT05585034Updated Aug 7, 2025

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

A Phase 1 interventional study of XmAb®808 and Keytruda® (pembrolizumab) in Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma and Non-small Cell Lung Cancer, Squamous or Non-squamous, sponsored by Xencor, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Xencor, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 216 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Enrollment
376th of 993
60 · median 41
Started
2022
with 56 others
Phase 1
362 of 1,099
71 open now
Registered
860th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 376th largest by enrollment of the 993 interventional ones that give a count, is one of 57 that started in 2022, is one of 362 in phase 1, and was the 860th registered.

Squamous Cell Carcinoma of Head and Neck

2,020 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

216 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

211 more — sign in →

All 216 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.

Read the detailed description

This is a Phase 1, open-label, first-in-human (FIH), multiple-dose, dose escalation study with cohort expansion at the RD, designed to evaluate the safety and tolerability of XmAb808 in combination with pembrolizumab. This study will be conducted in 2 parts: Part A (dose escalation) and Part B (cohort expansion).

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
  • Melanoma Excluding Uveal Melanoma
  • Non-small Cell Lung Cancer, Squamous or Non-squamous
  • Urothelial Carcinoma
  • Renal Cell Carcinoma, Clear Cell
  • Castration-resistant Prostate Cancer
  • Ovarian Cancer, Epithelial
  • TNBC - Triple-Negative Breast Cancer
  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Part A: confirmed advanced/ castration-resistant prostate adenocarcinoma, epithelial ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, urothelial carcinoma, melanoma, renal cell carcinoma, triple-negative breast cancer, or colorectal cancer that has progressed on standard therapies
  • Part B: Histologically confirmed advanced/metastatic castration-resistant prostate cancer that is PD1-naïve; head and neck squamous cell carcinoma that is PD1-naïve or has progressed on prior PD1 therapy; or melanoma that is PD1-naïve or has progressed on prior PD1 therapy
  • by 1.1; subjects with prostate cancer who have evaluable disease according to PCWG3 criteria may enroll
  • > 3 months
  • (ECOG) performance status of 0 or 1

Key Exclusion Criteria:

  • Subjects currently receiving other anticancer therapies
  • Any prior treatment with an agent targeting CD28
  • History of a life-threatening adverse event related to prior immunotherapy
  • Known active central nervous system involvement by malignant disease. Subjects with previously treated may participate provided they are radiologically and clinically stable
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Dose Escalation and Expansion XmAb®808 administered in combination with pembrolizumab

    XmAb®808 in combination with pembrolizumab

    Biological: XmAb®808 · Biological: Keytruda® (pembrolizumab)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Safety and tolerability as assessed by incidence of TEAEs, including clinically significant changes in safety laboratory tests and clinical findings

    Time frame: Up to 5 years

  2. Incidence of dose-limiting toxicities (DLTs)

    Safety and tolerability as assessed by incidence of DLTs and all available data which will be used to determine the optimal dose regimen

    Time frame: 49 days

Secondary outcomes

  1. Measurement of Cmax

    Peak plasma concentration (Cmax)

    Time frame: Through study completion, Up to 5 years

  2. Measurement of AUCtau

    Area under the plasma concentration versus time curve (AUCtau)

    Time frame: Through study completion, Up to 5 years

  3. Objective Response Rate

    Objective response rate by RECIST 1.1 assessment of CT/MRI imaging, as modified by PCWG3 for participants with prostate cancer

    Time frame: Through study completion, Up to 5 years

  4. Progression-free Survival

    Progression-free survival by RECIST 1.1 assessment of CT/MRI imaging, as modified by PCWG3 for participants with prostate cancer

    Time frame: Through study completion, Up to 5 years

  5. Duration of Response

    Duration of Response by RECIST 1.1 assessment of CT/MRI imaging, as modified by PCWG3 for participants with prostate cancer

    Time frame: Through study completion, Up to 5 years

07

Study locations

12 sites
  • UCLA Hematology/Oncology
    Los Angeles, California 90095, United States
  • Sarah Cannon Research Institute at HealthONE
    Denver, Colorado 80218, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Columbia University Irvine Medical Center
    New York, New York 10032, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15213, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute, University of Utah
    Salt Lake City, Utah 84112, United States
  • Froedtert Hospital & The Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in May 2025, 29 months.

Of 154 industry-sponsored phase 1 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 72. This study's 29 months is below that.

Counting every sponsor, half of 270 studies reached it within 49 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2022
First posted
Oct 18, 2022
StartActual
Dec 14, 2022
Primary completionActual
May 20, 2025
CompletionActual
May 20, 2025
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05585034
Lead sponsor
Xencor, Inc.
Responsible party
Sponsor
First posted
Oct 18, 2022
Start date
Dec 14, 2022
Primary completion
May 20, 2025
Completion
May 20, 2025
Last update
Aug 7, 2025

Study contacts

Mira Kistler, MD
study director · Xencor, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion